Predictive Oncology revenue was $1.25 m in FY, 2020
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 96.6k | 188.8k | 468.1k | 951.6k | 654.4k | 456.5k | 654.8k | 1.4m | 1.4m | 1.3m |
Revenue growth, % | 103% | (31%) | ||||||||
Cost of goods sold | 56.1k | 128.5k | 189.7k | 385.3k | 304.0k | 181.6k | 148.0k | 415.8k | 531.8k | 447.2k |
Gross profit | 40.6k | 60.2k | 278.4k | 566.2k | 350.4k | 274.9k | 506.8k | 995.9k | 879.8k | 805.1k |
Gross profit Margin, % | 42% | 32% | 59% | 60% | 54% | 60% | 77% | 71% | 62% | 64% |
Sales and marketing expense | 232.7k | 173.0k | 578.8k | 1.2m | 504.0k | 468.0k | 1.0m | 2.4m | 1.9m | 584.9k |
R&D expense | 15.0k | 406.0k | 289.0k | |||||||
General and administrative expense | 3.6m | 6.3m | 7.5m | 4.9m | 3.4m | 5.2m | 6.0m | 4.6m | 9.8m | 10.4m |
Operating expense total | 3.8m | 6.5m | 8.1m | 6.1m | 3.9m | 6.0m | 7.3m | 7.0m | 14.7m | 26.2m |
EBIT | (13.8m) | (25.4m) | ||||||||
EBIT margin, % | (976%) | (2025%) | ||||||||
Interest expense | 230.4k | 259.3k | 636.5k | 377.7k | 390.9k | 3.0 | ||||
Interest income | 510.3k | 287.1k | ||||||||
Investment income | (2.3m) | (439.6k) | ||||||||
Income tax expense | ||||||||||
Net Income | (4.5m) | (7.4m) | (9.4m) | (6.8m) | (4.8m) | (6.5m) | (7.7m) | (10.1m) | (19.4m) | (25.9m) |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|---|---|
Net Income | (4.5m) | (7.4m) | (9.4m) | (6.8m) | (4.8m) | (6.5m) | (7.7m) | (10.1m) | (19.4m) | (25.9m) |
Depreciation and Amortization | 3.2k | 1.1k | 148.8k | 63.0k | 78.6k | 82.4k | 71.6k | 147.6k | 704.9k | 1.0m |
Accounts Receivable | (50.3k) | 10.6k | (57.5k) | 39.7k | 19.3k | (636.0) | (98.6k) | (95.1k) | 143.3k | 69.9k |
Inventories | (97.6k) | (47.6k) | 23.0k | (245.2k) | 135.6k | (40.5k) | 7.2k | 24.0k | 91.1k | (94.7k) |
Accounts Payable | 71.7k | 421.1k | 429.0k | 1.1m | (1.5m) | (430.3k) | (79.6k) | 305.2k | 365.8k | (1.7m) |
Cash From Operating Activities | (1.8m) | (1.2m) | (3.9m) | (3.4m) | (7.5m) | (4.4m) | (4.5m) | (5.3m) | (8.7m) | (12.3m) |
Purchases of PP&E | (162.8k) | (101.4k) | (32.5k) | (32.8k) | (45.1k) | (177.7k) | (5.9k) | (298.4k) | ||
Cash From Investing Activities | (216.1k) | (121.2k) | (60.6k) | (422.9k) | (1.7m) | (1.1m) | (599.1k) | (167.5k) | ||
Long-term Borrowings | (16.3k) | (305.0k) | (1.2m) | (1.5m) | ||||||
Cash From Financing Activities | 1.9m | 1.1m | 4.2m | 3.4m | 12.4m | 1.7m | 5.1m | 5.8m | 9.3m | 13.0m |
Net Change in Cash | 113.6k | (109.8k) | 88.8k | (85.6k) | 4.8m | (3.1m) | (997.9k) | (604.0k) | (11.3k) | 527.5k |
Interest Paid | 31.0k | 146.1k | 145.8k |
USD | Q2, 2011 |
---|---|
Debt/Equity | -0.3 x |
Debt/Assets | 2.6 x |
Financial Leverage | -0.1 x |